ABT 614

Drug Profile

ABT 614

Alternative Names: ABT-614

Latest Information Update: 10 Feb 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Class Drug withdrawal therapies
  • Mechanism of Action Dopamine D3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Drug abuse

Most Recent Events

  • 10 Feb 2014 No development reported - Phase-I for Drug abuse in Canada (unspecified route)
  • 10 Feb 2014 No development reported - Phase-I for Drug abuse in USA (unspecified route)
  • 01 Aug 2009 Phase-I clinical trials in Drug abuse in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top